Actively Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Led by AstraZeneca · Updated on 2026-04-23
60
Participants Needed
11
Research Sites
218 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
CONDITIONS
Official Title
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant aged 18 years or older
- ECOG performance status of 0 to 1
- Provide an archival tumor specimen
- At least one measurable lesion according to RECIST v1.1
- Minimum life expectancy of 12 weeks
- Adequate and stable cardiac function
- Adequate bone marrow, liver, and kidney function
- Body weight of 35 kg or more
- Capable of giving signed informed consent
- For Module 1: Participants with select locally advanced or metastatic solid tumors who have received adequate standard of care
- For Module 2: Participants with Stage IV NSCLC who have received at least one prior metastatic treatment regimen or have PD-L1 expression of 1% or higher and no prior systemic therapy (first-line NSCLC)
You will not qualify if you...
- Severe or uncontrolled systemic diseases including respiratory, cardiac, or tumor-related conditions
- History or planned organ or allogeneic stem cell transplantation
- Active or prior documented autoimmune or inflammatory disorders within the past 3 years
- Prior toxicities that caused permanent discontinuation of immunotherapy
- Persistent toxicities grade 2 or higher from previous anti-cancer therapy
- Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids
- Untreated or symptomatic malignant spinal cord compression or history of leptomeningeal carcinomatosis
- Active uncontrolled or chronic hepatitis B or C infection
- Prior history of grade 3 or higher non-infectious pneumonitis
- Requirement of chronic immunosuppressive therapy including steroids over 10 mg prednisone/day or equivalent
- Receipt of live attenuated vaccine within 30 days
- For Module 2: Previous treatment with anti-TIGIT therapy
- For first-line NSCLC participants with actionable genetic alterations that have targeted therapy available as standard of care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Research Site
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
2
Research Site
St Louis, Missouri, United States, 63110
Actively Recruiting
3
Research Site
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
4
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
5
Research Site
San Antonio, Texas, United States, 78229
Actively Recruiting
6
Research Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
7
Research Site
East Melbourne, Australia, 3002
Actively Recruiting
8
Research Site
Chūōku, Japan, 104-0045
Actively Recruiting
9
Research Site
Kashiwa, Japan, 227-8577
Actively Recruiting
10
Research Site
Seoul, South Korea, 03080
Actively Recruiting
11
Research Site
Seoul, South Korea, 06351
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here